Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will complement commercial payload, linker and monoclonal antibodies services, offering fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
The bioconjugation suite will be located at Syngene's commercial biologics facility in Bengaluru, India.
Syngene will offer fully integrated services for ADCs.
Author's summary: Syngene International expands its capabilities.
More News
- Anglicans need more than one boat - THE OTHER CHEEK
- Praia Health’s Kurt Hammond on Powering Providence’s Work With Labcorp
- MCU: Jeremy Allen White Responds to Popular X-Men Fan Casting
- Fraternity and hope strengthen relations between Catholics and Anglicans
- Why Frustrated Boomers Are the Senior Living Industry’s Biggest Potential Disruptors
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Turkey Buys RAF's Retired C-130Js, Opening a New Chapter for Its Airlift Fleet
- Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
- Desperate need for water and food continues as Gaza families head north
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal